FDA approves twice-a-year injection for HIV prevention - CNN A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV Gilead Sciences, maker of the
Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . . Individuals must be tested for HIV-1 infection prior to initiating Yeztugo, and with each subsequent injection of Yeztugo, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection Drug-resistant HIV-1 variants have been identified with use of Yeztugo by individuals with undiagnosed HIV-1 infection
FDA Approves First Twice-a-Year HIV Prevention Shot Lenacapavir is the second long-acting drug approved to prevent HIV The first, Apretude, is given every two months and is used by about 21,000 Americans By comparison, nearly 500,000 people take
FDA approves twice-yearly shot of Gilead drug for HIV prevention The Food and Drug Administration has approved a new way to prevent HIV, clearing a Gilead Sciences drug that requires only two injections a year to protect against infections The treatment, known scientifically as lenacapavir and to be sold as Yeztugo, was approved on Wednesday to reduce the risk of sexually acquired HIV infections in adults and adolescents who weigh at least 35 kilograms
Regulators Approve Lenacapavir for H. I. V. Prevention The approval is among the most anticipated developments in the prevention of H I V But it arrives during deep cuts to global health programs that were expected to purchase and distribute the drug
For HIV AIDS, FDA approves next best thing to a vaccine | STAT HIV protection with just two shots a year: FDA approves Gilead drug Lenacapavir, to be sold as Yeztugo, has potential to bring AIDS pandemic to heel but faces Trump-era obstacles Manage alerts for